ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Vibostolimab/Pembrolizumab MK-7684A is on this study

  • The record lists it as a treatment, written “Pembrolizumab/Vibostolimab Co-Formulation”.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 2, 2026, 2:48 AM UTC
  • The role rule says the same.
  • So Vibostolimab/Pembrolizumab MK-7684A's page lists this study under “Testing it”.
24 links0 made here, not in the record37 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Sep 28Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT05007106MK-7684A With or WithoutOther Anticancer Therapiesin Participants WithSelected Solid Tumors(MK-7684A-005)(KEYVIBE-005)Merck Sharp & Dohme LLCPhase 2 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Sep 28 · ClinicalTrials.gov record · Version of 2026-09-28Version of 2026-09-28CONDITIONSUterine Cervical NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionEndometrial NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termSquamous Cell Carcinoma of …The registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termGallbladder NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termCholangiocarcinomaThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termEsophageal NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termTriple Negative Breast Neop…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termCarcinoma, HepatocellularThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termUrinary Bladder NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termOvarian NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termStomach NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termParkinson Disease 4, Autoso…The registry's MeSH filing›Nov 14 · Rule based · MisfiledMisfiledDRUGSVibostolimab/Pembrolizumab …Entry “Pembrolizumab/Vibostolimab Co-…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundLenvatinibIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerFluorouracilEntry “5-Fluorouracil”, read by our n…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCisplatinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundGemcitabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCarboplatinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundDocetaxelIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundBevacizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCapecitabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundOxaliplatinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Sep 28 · changes seen, not judgments
Nov 2Vibostolimab/Pembrolizumab MK-7684AClaude Opus 5.5TestedCurrent
Nov 2PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 2LenvatinibClaude Opus 5.5Background · partnerCurrent
Nov 2FluorouracilClaude Opus 5.5BackgroundCurrent
Nov 2CisplatinClaude Opus 5.5BackgroundCurrent
Nov 2PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 2GemcitabineClaude Opus 5.5BackgroundCurrent
Nov 2CarboplatinClaude Opus 5.5BackgroundCurrent
Nov 2DocetaxelClaude Opus 5.5BackgroundCurrent
Nov 2BevacizumabClaude Opus 5.5BackgroundCurrent
Nov 2CapecitabineClaude Opus 5.5BackgroundCurrent
Nov 2OxaliplatinClaude Opus 5.5BackgroundCurrent
Nov 14Uterine Cervical NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Endometrial NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Squamous Cell Carcinoma of Head and NeckRule based · condition-kind ruleFinest filed termCurrent
Nov 14Gallbladder NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14CholangiocarcinomaRule based · condition-kind ruleFinest filed termCurrent
Nov 14Esophageal NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Triple Negative Breast NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Carcinoma, HepatocellularRule based · condition-kind ruleFinest filed termCurrent
Nov 14Urinary Bladder NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Ovarian NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Stomach NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Parkinson Disease 4, Autosomal Dominant Lewy BodyRule based · condition-kind ruleMisfiledCurrent
Nov 18Vibostolimab/Pembrolizumab MK-7684ARule based · role ruleTestedAgrees
Nov 18PembrolizumabRule based · role ruleTestedOverridden
Nov 18LenvatinibRule based · role ruleBackgroundAgrees
Nov 18FluorouracilRule based · role ruleBackgroundAgrees
Nov 18CisplatinRule based · role ruleBackgroundAgrees
Nov 18PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18GemcitabineRule based · role ruleBackgroundAgrees
Nov 18CarboplatinRule based · role ruleBackgroundAgrees
Nov 18DocetaxelRule based · role ruleBackgroundAgrees
Nov 18BevacizumabRule based · role ruleBackgroundAgrees
Nov 18CapecitabineRule based · role ruleBackgroundAgrees
Nov 18OxaliplatinRule based · role ruleBackgroundAgrees
As of nowUterine Cervical NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.